INBX · Inhibrx Biosciences, Inc.
Market Cap
$1.54B
Shares
14.72M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$109.35
Open$106.45
Day$105.04–110.41
52W close$26.65–141.84
Avg vol 30d350K
Short int3.3M · 22.4% float · 10.4d
Short vol61%
Last earningsSep 8, 2026
DataMay 2024–Sep 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Jan 6, 2027
Est · unconfirmed
· in 15 wks
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$138.18M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-10,386.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$42.94M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.3%
Year over year · more shares
Price change (1Y)
+310.3%
Trailing year
Short interest
22.4%
Latest settlement · 10.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+21%
above
Price vs 50-day avg
+10%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
72%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+87%
trailing
YTD return
+38%
this year
Relative strength
+67%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $99 › 200d $90 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +49 funds added
Insider flow
Accumulating
Net +$3.7M over 90 days · 25% sells
Short interest
Rising
22.41% of float · ▲ +2.6% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
165 holders — near 2-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+550%
Y/Y
EPS growth
−108%
Y/Y
Free cash flow
$-129.8M
Quant / Vol
risk profile
Volatility
130%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+21%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
72%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $99 › 200d $90 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +49 funds added
Insider flow
Accumulating
Net +$3.7M over 90 days · 25% sells
Short interest
Rising
22.41% of float · ▲ +2.6% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
165 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $27
Now $109 · 72%
Range high $142
vs 200-day avg +21%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INBX
this stock
Inhibrx Biosciences, Inc.
|
$1.54B | +38.4% | +550.0% | — | 22.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.84B | +12.1% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.80B | +1.7% | +20.8% | 19.4 | 2.5% |
|
MRNA
Moderna, Inc.
|
$61.50B | +422.3% | +4.3% | — | 9.8% |
|
ARGX
Argenx SE
|
$60.93B | +17.8% | — | — | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INBX | +0.1% | +10.3% | +87.3% | -13.7% | +38.4% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | +0.4% | +10.4% | +67.2% | -13.0% | +26.7% |